{"a":[{"_":"Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market","$":{"href":"/biotech/roches-phase-3-win-tees-fight-novartis-blockbuster-kidney-disease-market","hreflang":"en"}}]}
Phase 3positivesefaxersenPositive
AI Analysis
Summary
Roche announced a Phase 3 win for sefaxersen, developed in partnership with Ionis, in kidney disease, positioning the candidate for regulatory discussions and potential blockbuster market opportunity.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial met primary endpoints
Importance:8/10
Sentiment:
0.75
Phase 3kidney diseasepartnershipregulatory approval pathwayblockbuster potential
Read the original article
Published by FierceBiotech on September 23, 2026 3:35 AM